Can Alpelisib combined with fulvestrant shrink tumors?

Alpelisib and fulvestrant (Fulvestrant) are often used in combination to treat hormone receptor-positive (HR- positive), HER2-negative advanced breast cancer, especially for those with PIK3CA gene mutations. The purpose of this combination therapy is to block the abnormally activated PI3K signaling pathway and inhibit hormone receptors through combined action to achieve a more effective anti-cancer effect.

Apelix, as a PI3K inhibitor, mainly affects the proliferation and survival of tumor cells by inhibiting the abnormal activation of the PI3K signaling pathway. Fulvestrant is a hormone therapy drug that inhibits the stimulation of estrogen on hormone receptor-positive breast cancer cells, thereby preventing the growth of cancer cells.

The combined treatment regimen of apelvis and fulvestrant aims to comprehensively utilize the different mechanisms of these two drugs to more comprehensively inhibit the proliferation of cancer cells. Some results from clinical trials show that this combination treatment regimen has achieved significant effects in some patients, including slowing disease progression and prolonging survival.

However, the specific effect on tumor shrinkage will vary depending on individual patient differences, disease characteristics, and treatment response. Some patients may experience tumor shrinkage, while for others, the primary effect of treatment may be stabilization or slowing of disease progression. Therefore, the evaluation of treatment effects usually requires a period of observation and monitoring, including imaging examinations (such as CT scans, MRI) and other efficacy evaluation indicators.

Apelis has not yet been launched in China, so it is not included in medical insurance. Therefore, patients cannot purchase it domestically and need to purchase Apelis through overseas channels. In foreign countries, the original Apelvis drug is mainly used. There are European and Indian versions of the original drug on the market. The price of the European version of the original drug is as high as tens of thousands of yuan. Relatively speaking, the price of the Indian version of the original drug is around four to five thousand yuan. The price is still relatively cheap. Moreover, the ingredients and efficacy of the European and Indian original drugs are consistent.